Harry Southworth - Concepedia

Author

Harry Southworth

AstraZeneca (United Kingdom)

Also Known As

H. SOUTHWORTH, Harry Southworth

Publications

706

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Bristol-Myers Squibb (United States)Lancaster University

About

Harry Southworth is an author at AstraZeneca (United Kingdom) specializing in medicine, engineering, and biostatistics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	471
2	Engineering	5	5	207
3	Biostatistics	4	4	68
4	Public Health	1	1	18
5	Biomedical Engineering	1	1	27

Harry Southworth

Publications

557

Citations

H-Index

Page 1

	Year	Citations
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia Anders Olsson, Helge Istad, O Luurila, American Heart Journal HypertensionLipid DisorderCardiovascular DiseasePharmacologyHyperlipidemia	2002	176
Good Signal Detection Practices: Evidence from IMI PROTECT A Wisniewski, Andrew Bate, Cédric Bousquet, Drug Safety EngineeringInformation SecuritySafety ScienceInformation ForensicsQuantitative Signal Detection	2016	139
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia Evan A. Stein, Kristina Strutt, Harry Southworth, The American Journal of Cardiology Metabolic SyndromeLipid DisorderVascular DiseaseHeterozygous Familial HypercholesterolemiaCardiovascular Disease	2003	106
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS Sarah Harris, Jonathan Q. Tran, Harry Southworth, Neurology Neuroimmunology & Neuroinflammation	2020	35
Use of acoustic emission to identify novel candidate biomarkers for knee osteoarthritis (OA) Daniela K Schlüter, Lucy Spain, Wei Quan, PLoS ONE EngineeringHigh-frequency Acoustic EmissionBiomedical EngineeringAcoustic SensorOrthopaedic Surgery	2019	27
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials Sarah Harris, Bruce Cree, Douglas L. Arnold, European Journal of Neurology	2021	20
Extreme value modelling of laboratory safety data from clinical studies Harry Southworth, Janet E. Heffernan Pharmaceutical Statistics EngineeringSafety ScienceInjury PreventionPotential Safety ConcernAdverse Drug Reaction	2012	18
Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran Harry Southworth Statistics in Medicine	2014	13
Detecting Outliers in Multivariate Laboratory Data Harry Southworth Journal of Biopharmaceutical Statistics Anomaly DetectionEngineeringData MiningStatistical AnalysisMedicine	2008	12
Multivariate extreme value modelling of laboratory safety data from clinical studies Harry Southworth, Janet E. Heffernan Pharmaceutical Statistics EngineeringLaboratory Safety DataSafety ScienceInjury PreventionAdverse Event	2012	11

Page 1